Pluristem Therapeutics Inc - Prometheus IP

Pluristem Therapeutics Inc., a leading developer of placenta-based cell therapy products, today announced that the U.S. Patent and Trademark Office has issued to the Company patent 9,096,827 titled “Adherent Cells From Placenta Tissue and Use Thereof in Therapy”. The patent protects specific methods of culturing placental adherent stromal cells, and use of these cells for...